Impact of superinfection on hospital length of stay and costs in patients with Ventilator-associated pneumonia

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 1, 2009, Pages 116-123

  Eagye, Kathryn J ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Bacteria resistance; Hospital costs; Length of stay; Superinfection; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; APACHE; COHORT STUDIES; COST OF ILLNESS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; SUPERINFECTION;

EID: 60549087902     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0028-1119815     Document Type: Article

References (29)

1. McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am 1998;12:761-779
2. George DL. Epidemiology of nosocomial pneumonia in intensive care unit patients. Clin Chest Med 1995;16: 29-44
3. Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL. Nosocomial pneumonia in Medicare patients: hospital costs and reimbursement patterns under the prospective payment system. Arch Intern Med 1991;151:1109-1114
4. Dietrich ES, Demmler M, Schulgen G, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002;30:61-67
5. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903
6. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317
7. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:2115-2121
8. Hugonnet S, Eggimann P, Borst F, et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004;25:1090-1096
9. Koontz CS, Chang MC, Meredith JW. Effects of empiric antibiotic administration for suspected pneumonia on subsequent opportunistic pulmonary infections. Am Surg 2000; 66:1110-1114
10. Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991;100:439-444
11. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59
12. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug- resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43-48
13. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003;31:1035-1041
14. Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006;34:700-706
15. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371-1375
16. Health Care Performance Measurement Initiatives-2006. Available at: http://www.jointcommission.org/Physicians/md-pi.htm. Accessed November 13, 2007
17. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-190
18. Fowler RA, Flavin KE, Barr J, et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003;123:835-844
19. American Thoracic Society: Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
20. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 2000;132:621-630
21. Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005;33:1266-1271
22. Chelluri L, Mendelsohn AB, Belle SH, et al. Hospital costs in patients receiving prolonged mechanical ventilation: does age have an impact? Crit Care Med 2003;31:1746-1751
23. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888
24. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124-1130
25. Combes A, Luyt CE, Fagon JY, et al. Early predictors for infection recurrence and death in patients with ventilator- associated pneumonia. Crit Care Med 2007;35:146-154
26. Chastre J, Luyt CE, Combes A, Trouillet JL. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin Infect Dis 2006;43:S75-S81
27. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109-1115
28. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598
29. Kuti JL, Nicasio AM, Shore E, et al. Outcomes of an empiric antibiotic algorithm (EAA) for ventilator associated pneumonia (VAP) that considers local MIC distributions and pharmacodynamics [abstract 1093]. 45th Annual Meeting of the Infectious Diseases Society of America; San Diego, CA, October 4-7, 2007